PT-141 vs Melanotan II

The evidence is concerning enough that multiple national drug regulators have issued warnings. Australia's TGA issued a formal warning in November 2025 specifically about melanotan II's association with melanoma and other skin cancers. European agencies issued similar warnings earlier. Mechanistically, MC1R activation (melanotan II's main tanning pathway) overlaps with melanogenesis pathways implicated in some melanoma subtypes. Case reports document atypical mole development and progression in users. It is not a definitive causal link but it is a serious enough signal that regulators are moving.

Technically PT-141 (Vyleesi) is FDA approved only for premenopausal women with hypoactive sexual desire disorder. Off-label prescribing for men and for other sexual dysfunction indications does happen through some telehealth platforms and specialty clinics. It requires a prescription from a doctor willing to prescribe off-label. The active ingredient is bremelanotide, the brand is Vyleesi, and it is manufactured by Cosette Pharmaceuticals with patient assistance pricing at $99 for four doses.

Melanotan II is a non-selective melanocortin agonist - it hits MC1R (skin pigmentation), MC3R, and MC4R. PT-141 is relatively selective for MC4R, the receptor subtype associated with sexual function. MC1R activation drives melanogenesis in skin, which produces the tanning effect melanotan II was originally developed for. The selectivity difference is also why PT-141 has a much cleaner side effect profile - no pigmentation changes, no mole development, just the sexual function effect plus the usual transient side effects like nausea and flushing.

Same active molecule, three names. Bremelanotide is the generic INN name. PT-141 was the original development code. Vyleesi is the brand name approved by the FDA in 2019 for HSDD in premenopausal women, marketed by Cosette Pharmaceuticals (which acquired it from Palatin Technologies). When you see PT-141 in research peptide catalogs, it is chemically the same as prescription Vyleesi but without the quality control, medical supervision, or patient assistance pricing of the legal product.

PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. Melanotan II works via Melanocortin receptor agonist that stimulates melanogenesis for tanning and has effects on. They differ in FDA approval status, efficacy data, and cost.

PT-141 typically costs $800 - $1,200/mo, while Melanotan II costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

PT-141 is FDA-approved. Melanotan II is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of Melanotan II include Nausea, Flushing, Spontaneous erections. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.